China Biosimulation Market (2026-2031)
The China Biosimulation Market was valued at $196.8 Million in 2026 and projected to reach to $458.3 Million by 2031, representing a compound annual growth rate of 18.4%. China's biosimulation market is positioned for exceptional growth driven by government support for pharmaceutical innovation, increased R&D spending, and regulatory acceptance of computational methods.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Biosimulation Market Trends and Insights
- This robust growth trajectory reflects China's increasing investment in pharmaceutical R&D, regulatory modernization, and adoption of computational modeling technologies.
- China is leveraging biosimulation to accelerate drug development timelines and reduce preclinical testing costs, positioning itself as a key player in the Asia Pacific biosimulation landscape. The 18.4% compound annual growth rate underscores China's commitment to integrating advanced simulation technologies into its healthcare and pharmaceutical sectors.
- China's expanding biopharmaceutical industry, coupled with government initiatives supporting innovation and digital health infrastructure, drives demand for biosimulation solutions.
- By 2031, China is expected to capture significant market share as domestic and multinational pharmaceutical companies increasingly adopt these technologies for drug discovery, development, and regulatory submissions..
Key Market Statistics
- CAGR (2026-2031) 18.4% CAGR
- Market Size, 2026 ~USD 196.8 Million
- Forecast, 2031 ~USD 458.3 Million
- Country China
China Biosimulation Market Overview
Rapid Market Expansion :
China's biosimulation market is projected to grow from $196.8 million in 2026 to $458.3 million by 2031, representing an 18.4% CAGR, outpacing the global average of 16.7%.
Regulatory Modernization :
China's regulatory agencies are increasingly accepting computational modeling and simulation data in drug approval processes, accelerating the adoption of biosimulation technologies across the pharmaceutical sector.
R&D Investment Surge :
Chinese pharmaceutical companies are significantly increasing R&D budgets and shifting toward computational approaches to reduce development timelines and costs in competitive global markets.
Technology Adoption Growth :
Rising adoption of advanced computational modeling, artificial intelligence, and digital twin technologies among Chinese biotech firms is driving demand for sophisticated biosimulation solutions.
China Biosimulation Market Dynamics
- The country's focus on reducing drug development timelines and costs while improving efficacy predictions is accelerating biosimulation adoption across domestic and multinational pharmaceutical companies operating in China. The market will benefit from China's expanding biotech ecosystem, talent development in computational sciences, and integration of AI-driven modeling platforms.
- Strategic partnerships between Chinese firms and global biosimulation providers, combined with regulatory harmonization initiatives, will further propel market expansion through 2031..
Related Ecosystem
Healthcare It
Key Takeaways
- China's biosimulation market will grow from $196.8M (2026) to $458.3M (2031), representing an 18.4% CAGR.
- China's pharmaceutical R&D investments and regulatory modernization are primary catalysts for biosimulation adoption.
- China is positioning itself as a regional hub for computational drug development within Asia Pacific.
- By 2031, China's biosimulation market will more than double, driven by domestic innovation and multinational expansion.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | DATA ANALYSIS & INTERPRETATION (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | SOFTWARE (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Offering, Type, Phase Of Development |
China Biosimulation Market Report Segmentation
3 segment dimensions are covered across the global market.
By Offering
- Services
- Software
By Type
- Consulting & Advisory
- Data Analysis & Interpretation
- Implementation, Training, And Support
By Phase Of Development
- Commercial & Market Access
- Drug Discovery
- Early Clinical Development
- Late Clinical Development
- Preclinical Development
- Regulatory
CHINA: BIOSIMULATION MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 21.2 | 24.6 | 28.7 | 33.4 | 39 | 45.6 | 53.5 | 62.8 | 17 |
| CONTRACT RESEARCH ORGANIZATIONS | 38.3 | 45.3 | 53.5 | 63.5 | 75.4 | 89.7 | 107 | 127.8 | 19 |
| OTHER END USERS | 10.4 | 11.7 | 13.1 | 14.6 | 16.2 | 17.9 | 19.8 | 21.7 | 10.7 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 118.3 | 140.4 | 167 | 198.9 | 237.4 | 284 | 340.3 | 408.7 | 19.6 |
| REGULATORY BODIES | 8.3 | 9.6 | 11.3 | 13.2 | 15.5 | 18.3 | 21.6 | 25.5 | 17.7 |
| TOTAL | 196.5 | 231.6 | 273.5 | 323.6 | 383.4 | 455.6 | 542.2 | 646.5 | 18.8 |
Target Audience
- Pharmaceutical Companies : Chinese and multinational pharma firms need China-specific biosimulation market data to optimize R&D strategies, reduce development costs, and navigate regulatory requirements for faster drug approvals.
- Biotech & CRO Firms : Biotech startups and contract research organizations operating in China require market insights to identify biosimulation service opportunities, assess competitive positioning, and plan expansion strategies.
- Software & Technology Providers : Biosimulation software vendors and computational modeling platform developers need China market analysis to understand adoption rates, customer segments, and localization requirements for market penetration.
- Investment & Private Equity : Investors and PE firms evaluating opportunities in China's biotech sector require detailed market data to assess growth potential, identify acquisition targets, and evaluate portfolio company performance.
- Regulatory & Policy Bodies : Chinese regulatory agencies and government bodies need market intelligence to inform policy decisions, support pharmaceutical innovation initiatives, and align biosimulation acceptance with international standards.
Key Companies in the China Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China ($196.8M in 2026, $458.3M in 2031) to support investment decisions, business planning, and competitive positioning in this high-growth market.
- Regulatory Landscape Intelligence : Understand China's evolving regulatory acceptance of biosimulation data, enabling companies to align product development strategies with local approval requirements and accelerate market entry.
- Competitive Benchmarking : Analyze China-specific market dynamics, key players, and adoption rates to identify competitive advantages, partnership opportunities, and gaps in the biosimulation solution landscape.
- Strategic Investment Guidance : Leverage detailed China market insights to make informed decisions on R&D investments, technology acquisitions, and market expansion strategies in Asia's largest pharmaceutical market.
- Technology Adoption Trends : Identify emerging biosimulation technologies, AI integration patterns, and computational modeling preferences among Chinese pharmaceutical and biotech companies to guide product development.
Frequently asked questions
What is the current size of China's biosimulation market?
China's biosimulation market was valued at $196.8 million in 2026 and is projected to reach $458.3 million by 2031.
What is the growth rate of China's biosimulation market?
China's biosimulation market is growing at a compound annual growth rate (CAGR) of 18.4% from 2026 to 2031.
What factors are driving biosimulation adoption in China?
China's biosimulation growth is driven by increased pharmaceutical R&D investment, regulatory modernization, digital health infrastructure development, and the need to reduce preclinical testing costs.
How does China's biosimulation market compare to the global market?
China's 18.4% CAGR exceeds the global biosimulation market CAGR of 16.7%, indicating faster growth and increasing market significance within Asia Pacific.
Which sectors in China are adopting biosimulation technologies?
China's pharmaceutical and biopharmaceutical sectors are primary adopters, including domestic companies and multinational firms conducting drug discovery, development, and regulatory submission activities.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- US Biosimulation Market
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- UK Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- Australia Biosimulation Market
- South Korea Biosimulation Market
- Brazil Biosimulation Market
- Mexico Biosimulation Market
- Saudi Arabia Biosimulation Market
- UAE Biosimulation Market
- South Africa Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
